Evidence map›Paper›PMID 25933006›Full record

ArticlePloS one2015

Copy Number Variation at the APOL1 Locus.

Rupam Ruchi, Giulio Genovese, Jessica Lee, Victoria T Charoonratana, Andrea J Bernhardy, Seth L Alper, Jeffrey B Kopp, Ravi Thadhani, David J Friedman, Martin R Pollak

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Frontiers in medicine · 2022
    Article
  5. Article
  6. Article
  7. Apolipoprotein L1 nephropathies: 2017 in review.Current opinion in nephrology and hypertension · 2018
    Review
  8. Article
  9. Article
  10. Human genetics of nephrotic syndrome and the quest for precision medicine.Current opinion in nephrology and hypertension · 2016
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Rupam RuchiDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Division of Nephrology, Department of Medicine, University of Florida, Gainesville, Florida, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America.
Giulio GenoveseStanley Center, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America.
Jessica LeeDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Victoria T CharoonratanaDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Andrea J BernhardyDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Seth L AlperDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America; Stanley Center, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America.
Jeffrey B KoppKidney Diseases Branch, National Institutes of Health, Bethesda, Maryland, United States of America.
Ravi ThadhaniRenal Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
David J FriedmanDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Martin R PollakDivision of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America.
Beth Israel Deaconess Medical Center · USHarvard University · USBroad Institute · USMassachusetts General Hospital · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Florida · US

Funding

Focal Segmental Glomerulosclerosis: Genetics & MechanismsZIADK043308 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOPP, JEFFREY BURNETT · 2009 to 2024
$15.7M
The Genetic Basis of FSGSR01DK054931 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI POLLAK, MARTIN R. · 1999 to 2017
$6.2M
APOL1 variants: Understanding the basis of disparities in rates of kidney diseaseR01MD007092 · NIMHD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FRIEDMAN, DAVID J, POLLAK, MARTIN R. · 2012 to 2021
$4.3M
NIDDK NIH HHS R01 DK054931NIMHD NIH HHS MD007092NIMHD NIH HHS R01 MD007092
6 · The paper itself

Abstract

Two coding variants in the APOL1 gene (G1 and G2) explain most of the high rate of kidney disease in African Americans. APOL1-associated kidney disease risk inheritance follows an autosomal recessive pattern: The relative risk of kidney disease associated with inheritance of two high-risk variants is 7-30 fold, depending on the specific kidney phenotype. We wished to determine if the variability in phenotype might in part reflect structural differences in APOL1 gene. We analyzed sequence coverage from 1000 Genomes Project Phase 3 samples as well as exome sequencing data from African American kidney disease cases for copy number variation. 8 samples sequenced in the 1000 Genomes Project showed increased coverage over a ~100kb region that includes APOL2, APOL1 and part of MYH9, suggesting the presence of APOL1 copy number greater than 2. We reasoned that such duplications should be enriched in apparent G1 heterozygotes with kidney disease. Using a PCR-based assay, we observed the presence of this duplication in additional samples from apparent G0G1 or G0G2 individuals. The frequency of this APOL1 duplication was compared among cases (n = 123) and controls (n = 255) with apparent G0G1 heterozygosity. The presence of APOL1 duplication was observed in 4.06% of cases and 0.78% controls, preliminary evidence that this APOL1 duplication may alter susceptibility to kidney disease (p = 0.03). Taqman-based copy number assays confirmed the presence of 3 APOL1 copies in individuals positive for this specific duplication by PCR assay, but also identified a small number of individuals with additional APOL1 copies of presumably different structure. These observations motivate further studies to better assess the contribution of APOL1 copy number on kidney disease risk and on APOL1 function. Investigators and clinicians genotyping APOL1 should also consider whether the particular genotyping platform used is subject to technical errors when more than two copies of APOL1 are present.

Indexed as

DNA Copy Number VariationsGene DuplicationGenetic Predisposition to DiseaseApolipoprotein L1ApolipoproteinsApolipoproteins LBlack or African AmericanCase-Control StudiesGene ExpressionGene FrequencyGenes, RecessiveGenetic LociGenome, HumanHeterozygoteHuman Genome ProjectHumansAPOL1 protein, humanAPOL2 protein, humanApolipoprotein L1ApolipoproteinsApolipoproteins LLipoproteins, HDLMolecular Motor ProteinsMYH9 protein, humanMyosin Heavy Chains

Identifiers

PMID25933006
PMCPMC4416782
OpenAlexW2044573879

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.